Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point.

@article{Decensi2000RandomizedTO,
  title={Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point.},
  author={Andrea U. Decensi and R. L. Torrisi and Silvia Bruno and Massimo Costantini and Antonio Gerardo Curotto and Guido Nicol{\`o} and Bruno Malcangi and Laura Baglietto and Gian Paolo Bruttini and Beatrice Gatteschi and Gabriella Rondanina and Marco Varaldo and Marjorie Perloff and Winfred F. Malone and Paolo Bruzzi},
  journal={Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology},
  year={2000},
  volume={9 10},
  pages={1071-8}
}
Retinoids have shown a potential activity in preventing tumor recurrence in superficial bladder cancer. We assessed the activity of the synthetic retinoid fenretinide in superficial bladder cancer using DNA flow cytometry and conventional cytology as surrogate biomarkers. A total of 99 subjects with resected superficial bladder cancer (pTa, pT1) were randomized to either fenretinide (200 mg day p.o. for 24 months) or no intervention. Cystoscopy and bladder washing for DNA flow cytometry end… CONTINUE READING
Highly Cited
This paper has 34 citations. REVIEW CITATIONS